BeStock  

Global Partners GLP

US equityMarket cap rank #2904Oil & Gas Midstream
$42.13 −$1.13 (-2.61%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $42.13 0.00%
Open$43.01
Prev close$43.26
Day range$41.92 – $43.07
Volume80.4K
Market cap$1.43B
P/E (TTM)7.7
Dividend yield7.26%

GLP Stock News

Headlines matching Global Partners or the GLP ticker, most recent first.

  • Accelerating global expansion! Hengrui Pharma licenses its oral GLP-1/GIP weight-loss drug to Novo-Nordisk A/S, with potential deal value reaching up to $2.6 billion. Mixedwallstreetcn · 29 Sep 2026 · Direct mention
  • Hengrui Pharma Seals Up to US$2.6 Billion Global Licensing Deal With Novo Nordisk for Oral GLP-1/GIP DrugTipRanks · 29 Sep 2026 · Direct mention
  • Will GLP-1s Hurt Food Stocks? Assessing the Changing Consumer.Yahoo Finance · 24 Sep 2026 · Direct mention
  • Raymond James Initiates Global Partners(GLP.US) With Hold RatingMarket news · 11 Aug 2026 · Direct mention
  • ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF TWO PHASE I STUDIES INU.S. FOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, AN AMYLIN RECEPTOR PEPTIDE AGONIST, ANDASC36_35FDC ONCE-MONTHLY INJECTION, A CO-FORMULATION OFASC36 AND GLP-1R/GHKEX · 10 Aug 2026 · Direct mention
  • ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS SUBMITS TWO IND APPLICATIONS TO THE U.S. FDAFOR THE TREATMENT OF OBESITY: ASC36 ONCE-MONTHLYINJECTION, A PEPTIDE AMYLIN RECEPTOR AGONIST,AND ASC36_35 FDC ONCE-MONTHLY INJECTION,A CO-FORMULATION OF ASC36 PLUS PEPTIDE GLP-1RHKEX · 6 Jul 2026 · Direct mention
  • ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR PHASE I STUDYOF ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR DUAL PEPTIDE AGONIST, ASC35, FOR THE TREATMENT OF OBESITYHKEX · 23 Jun 2026 · Direct mention
  • Yinuos (688710): Nantong Yinuos' "High-Quality Non-Clinical Innovative Drug Comprehensive Evaluation Platform Expansion Project" has obtained NMPA GLP certification. PositiveNortheast Securities · 11 Jun 2026 · Direct mention
  • ASCLETIS-B: VOLUNTARY ANNOUNCEMENT - ASCLETIS COMPLETES ENROLLMENT IN U.S. PHASE II STUDY OFASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST, FOR THETREATMENT OF DIABETESHKEX · 27 Apr 2026 · Direct mention
  • Jiaze Renewables Corporation: Jiaze New Energy Co., Ltd. Simplified Equity Change Report (Information Discloser: GLP Renewable Energy Investment I Limited)SZSI · 15 Apr 2026 · Direct mention
  • Neutral Outlook on Magnum Ice Cream Co.: Soft Demand, Margin Pressure, and GLP-1 Risks Cap Near-Term UpsideTipRanks · 12 Feb 2026 · Direct mention
  • U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk -- WSJWSJ · 9 Nov 2026 · Direct mention
  • Hims & Hers Struck a GLP-1 Deal With Lilly. Its Stock Is Rallying.MarketWatch · 7 Nov 2026 · Direct mention
  • Multiple GLP-1 injectables have been included in the National Reimbursement Drug List (NRDL) for the first time, including products from Pfizer and Innovent Biologics, for the treatment of type 2 diabetes in adults.Sina Tech · 14 Nov 2026 · Direct mention
  • Leading Novo Nordisk! China's first oral GLP-1 weight-loss drug has been approved and production has already begun ahead of schedule. Mixedcls.cn · 12 Nov 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on GLP.

Sign in to join the discussion.

Scroll to Top